Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 7/20 | 0.70 |
| ▸ | TP53 | P04637 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | PLAU | P00749 | 1/20 | 0.58 |
| ▸ | EHMT2 | Q96KQ7 | 6/20 | 0.56 |
| ▸ | PLAUR | Q03405 | 4/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2628848 | 0.95 | NTRK1 (0.74) | NTRK1MAPTTP53POLBTHRB | |
| SCHEMBL16978027 | 0.87 | NTRK1 (0.81) | NTRK1MAPTTP53POLBTHRB | |
| SCHEMBL19262255 | 0.86 | NTRK1 (0.67) | NTRK1MAPTTP53POLBTHRB | |
| SCHEMBL13284987 | 0.85 | NTRK1 (1.00) | NTRK1MAPTTP53POLBTHRB | |
| SCHEMBL13284981 | 0.84 | NTRK1 (0.81) | NTRK1MAPTTP53POLBTHRB | |
| SCHEMBL16978029 | 0.84 | NTRK1 (0.78) | NTRK1MAPTTP53POLBTHRB | |
| SCHEMBL16037129 | 0.84 | NTRK1 (0.86) | NTRK1MAPTTP53POLBTHRB | |
| SCHEMBL2480771 | 0.83 | NTRK1 (0.84) | NTRK1MAPTTP53POLBTHRB | |
| SCHEMBL15940264 | 0.83 | MAPT (0.81) | NTRK1MAPTTP53POLBTHRB | |
| SCHEMBL13284992 | 0.83 | NTRK1 (0.76) | NTRK1MAPTTP53POLBTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190296-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190296-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| US-8389730-B2 | Compositions and methods for the treatment of disease associated with TRP-P8 expression | DENDREON CORPORATION (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389730-B2 | Compositions and methods for the treatment of disease associated with TRP-P8 expression | DENDREON CORPORATION (US) | 2013-03-05 | — | — | US | disclosed |
| US-8362264-B2 | Tryptophan antagonist; anticancer agents | DENDREON CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362264-B2 | Tryptophan antagonist; anticancer agents | DENDREON CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190296-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | NTRK1 176/4885MAPT 2258/4885TP53 101/4885 |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | NTRK1 154/4885MAPT 3379/4885TP53 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.